Anteris Technologies Announces One-Year Clinical Outcomes for DurAVR® THV to be Presented at TCT® 2025

Stock Information for Orchestra BioMed Holdings Inc Com

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Orchestra BioMed Holdings Inc Com

Anteris Technologies Presents Data from 100 DurAVR® THV Patients at PCR London Valves
Anteris Announces Results for the Third Quarter of 2025
FDA Approves Anteris's DurAVR® THV Global Pivotal Trial (the "PARADIGM Trial")
Anteris DurAVR® THV Demonstrates Favorable Hemodynamics in Small Annuli Patients with no Valve Related Mortality at One Year
Anteris Technologies Announces First Patients Treated in DurAVR® THV Global Pivotal Trial (the "PARADIGM Trial")
Anteris Receives First European Regulatory Clearance to Commence DurAVR® THV Global Pivotal Trial (the "PARADIGM Trial")
Anteris Technologies Global Corp. Announces Adjournment of Special Meeting of Stockholders
Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.